About 75% of people aged 45-74 are overweight or obese in England and the cost to the NHS is anything from £6.5 billion to £11 billion. In a bid to tackle increasing nationwide obesity, the NHS now offers weight-loss drugs to people who meet certain criteria. The most common weight-loss drugs on offer are Wegovy (semaglutide) and Mounjaro (tirzepatide), and these are injected using an injection pen. However, there are issues with their use, including normalising weight loss medications, unregulated sellers and their use by people with eating disorders. Along with potential weight loss, the drugs can have other positive and negative health benefits